Navigation Links
Genomic Health Announces Positive Topline Results of Large Prostate Cancer Clinical Validation Study; Company to Proceed with 2013 Commercial Launch
Date:9/18/2012

otype DX Genomic Prostate Score.  In a three year effort, Genomic Health optimized its proprietary RT-PCR methodology to be able to analyze the very small amounts of formalin-fixed paraffin-embedded prostate tissue obtained by diagnostic prostate needle biopsies.

"The over-treatment of prostate cancer represents one of the most significant issues in men's health today," said Howard Soule, Executive Vice President and Chief Science Officer of the Prostate Cancer Foundation. "With this study, Genomic Health has applied its groundbreaking technology and innovative clinical trial expertise to address a critical treatment decision facing hundreds of thousands of men each year."

Genomic Health conducted six feasibility and development studies in collaboration with the Cleveland Clinic evaluating more than 700 patients and 700 candidate genes to select the genes for this test.  The resulting pre-specified test was then evaluated in prostate needle biopsy specimens in the prospectively-designed UCSF clinical validation study.  It is expected that in conjunction with the Gleason grading system and conventional parameters such as PSA, age, and physical examination, the Oncotype DX Genomic Prostate Score will be utilized to personalize prostate cancer treatment based on the underlying biology of an individual patient's tumor.

"Each year in the U.S. alone, more than 240,000 men are diagnosed with prostate cancer, with the vast majority receiving aggressive treatments associated with serious, long-term side effects.  Based on the results of this study, we believe the Oncotype DX Genomic Prostate Score will increase the number of patients eligible for active surveillance, and identify those who should consider aggressive treatment," said Steven Shak, Executive Vice President of Research and Development and Chief Medical Officer at Genomic Health.  "With our proven record of developing and validating multi-gene t
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
2. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
3. Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium
4. Genomic Health Announces Year-End 2011 Financial Results, Provides 2012 Financial Outlook
5. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
6. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
7. Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing
8. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
9. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
10. Rosetta Genomics Pays Off Secured Loan and Reclaims Unencumbered Rights to All Assets
11. Webinar Announcement: GenomeSpace: A New Solution for Integrating Genomic Analysis Tools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... WASHINGTON D.C., September 30, 2014 Applying a ... of researchers at Harvard University has demonstrated the ... surface -- work that holds promise for making ... and detailing the sides of next-gen rocket ships ... When light passes through oil in water, it ...
(Date:9/30/2014)... 30, 2014 Report Details Biosimilar ... potential revenues Do you want to find sales ... revenue predictions for those biological drugs from 2014, ... find financial data, R&D trends, opportunities and selling ... forecasts to 2024 at overall world market, therapeutic ...
(Date:9/30/2014)... Proove Biosciences , the commercial and research leader ... genetic test built upon research from their published P.A.I.N. ... provide physicians with an objective way to understand theirs ... between individuals. With this new test, physicians will be ... predisposition that will affect their pain tolerance. , The ...
(Date:9/30/2014)... 30, 2014 Fast, semi-automatic ... chemistry in documents ChemAxon , ... consulting services for life science research, launches ChemCurator, ... Markush structures from documents. Markush structures ... however generating and understanding Markush structures is a ...
Breaking Biology Technology:Taking thin films to the extreme 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2
... FULTON, Miss., March 20, 2012  Frank A. Critz, M.D., founder ... honored with a hometown hero,s welcome this April when he ... prostate cancer survivors.  The event will be April 14, 2012 ... Street in Fulton from noon until 3 p.m., and lunch ...
... DIEGO, March 20, 2012   CareFusion announced today ... Food and Drug Administration (FDA) for its new electrodiagnostic ... EDX system is a multi-modality device for monitoring and ... system. (Logo: http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO ) ...
... LAKE CITY, March 20, 2012 Remedy Informatics, the ... research, announced that Renton, Wash.-based Providence Health & ... registries for their Orthopedic Institute and Telestroke Network to ... http://photos.prnewswire.com/prnh/20120206/SF47874LOGO ) "We are excited to work ...
Cached Biology Technology:Radiotherapy Clinics of Georgia's Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award 2CareFusion Announces 510(k) Clearance and U.S. Launch of New Advanced Electrodiagnostic System 2Providence Health & Services Inks Deal with Remedy Informatics for Orthopedic and Stroke Registries 2Providence Health & Services Inks Deal with Remedy Informatics for Orthopedic and Stroke Registries 3
(Date:9/30/2014)... any aquatic environment on Earth, but when the climate ... to the limit. The amount of time needed to ... different species cope in the future, reveals a new ... in the scientific journal Proceedings of the Royal ... to increasing levels of greenhouse gases in the atmosphere. ...
(Date:9/30/2014)... in Munich report that a new class of ... chemotherapeutic drugs. They have also pinpointed the relevant ... anti-tumor agents. , Researchers led by LMU,s ... the Technische Universitt Mnchen have identified a class ... in the fight against malignant tumors. The compound ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... 2012) - The many factors that contribute to how cells ... not fully understood, but researchers at Baylor College of ... intracellular membranes fuse, and in the process, created a new ... the current edition of the journal PLoS Biology . ...
... Cytori Therapeutics (NASDAQ: CYTX) announced today the publication ... Company,s European clinical trial evaluating adipose-derived stem and ... infarction (heart attack or AMI), as Research Correspondence ... of Cardiology . The APOLLO trial was a ...
... (NAS) has awarded John Waterbury, scientist emeritus in the ... the 2012 Gilbert Morgan Smith Medal. Waterbury is ... recognition of their extraordinary scientific achievements in a wide ... sciences. The recipients will be formally recognized in a ...
Cached Biology News:Membrane fusion a mystery no more 2Adipose stem cell heart attack trial data published in JACC 2WHOI's John Waterbury receives NAS Gilbert Morgan Smith Medal 2
... is a 96-well ELISA-compatible plate containing ... (mouse IgG 1 ) is directed ... (GST), and binds with high affinity ... in which the tag is exposed. ...
... Laboratory (RTL) can provide you with ... ,,Microbial method development and validation ,Performance ... conditions of your GMP manufacturing environment ... offer a full spectrum of microbiological ...
... years of experience in the development of ... to large and small peptides, proteins, haptens, ... DNA-encoded antigens. We understand and appreciate that ... development programs are never "cookbook". We will ...
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
Biology Products: